For a 57-year-old postmenopausal woman with a T3, ER+, HER2-negative invasive lobular carcinoma, which of the following would you choose?
online surveys
Assuming commercial availability or an open clinical trial, which do you consider most effective/promising for platinum-sensitive epithelial ovarian cancer?
customer surveys